Multiple myeloma blood tests work together to answer different questions. Serum protein electrophoresis (SPEP) looks for an abnormal protein pattern and can measure an M-protein. Serum immunofixation identifies its type. The serum free light chain test measures unbound antibody fragments and their balance. Blood counts, calcium, and kidney findings help show whether a plasma-cell disorder may be affecting the body. None of these results alone establishes active multiple myeloma. Diagnosis may require a bone marrow examination, imaging, and a specialist’s assessment. [1], [2], [3]
This guide focuses on interpreting myeloma-related findings. For the broader role of laboratory testing in cancer care, see Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps. If test names and panels are unfamiliar, start with The Complete Guide to Lab Tests and Blood Work.
Multiple myeloma is a cancer of plasma cells, which normally make antibodies to help fight infection. An abnormal group of plasma cells may produce many copies of one antibody or antibody fragment. This is called a monoclonal protein, M-protein, or paraprotein. Some myelomas produce mainly free light chains, and a small minority produce little or no measurable protein. [1], [3]
The evaluation therefore asks two connected questions: Is there evidence of an abnormal antibody-producing cell population, and is it causing clinically important disease? A protein result addresses the first question; blood counts, chemistry results, urine assessment, imaging, and sometimes tissue testing help address the second.
| Test | Main question | Key limitation |
|---|---|---|
| SPEP | Is there a restricted protein pattern, and is an M-protein measurable? | A small or light-chain-only abnormality may not produce a clear M-spike. |
| Serum immunofixation (IFE) | What heavy-chain and light-chain type is present? | Identifies a protein type; does not establish active myeloma or measure its amount. |
| Serum free light chains with ratio | Are free kappa and lambda concentrations unusually imbalanced? | Kidney function, immune activity, and the assay affect interpretation. |
| Complete blood count (CBC) with differential and platelets | Is there anemia or another blood-cell abnormality? | An abnormal blood count has many possible causes. |
| Comprehensive metabolic panel (CMP) | Are kidney function, calcium, or protein measurements abnormal? | Organ abnormalities must be evaluated for their cause. |
These tests support a targeted investigation or a monitoring plan. They are not a universal cancer-screening panel. [3], [4], [7]
SPEP separates serum proteins into groups. A narrow, concentrated band or peak can suggest a monoclonal protein. When measurable, the laboratory may report its concentration as an M-spike. A broad increase in antibody-related proteins more often reflects a polyclonal response, meaning many immune-cell populations are contributing. The laboratory’s interpretation helps distinguish these patterns. [2], [3]
An M-spike is a finding, not a diagnosis. It may occur in monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, active myeloma, or another monoclonal-protein disorder. Its significance depends on the protein type, amount, changes over time, and other findings. [9]
A report without a measurable M-spike does not end the investigation if symptoms or related results remain concerning. Small monoclonal proteins and free light chains may require the other protein tests to detect or characterize them. [3]
Serum immunofixation helps identify an abnormal protein’s type, such as IgG kappa or IgA lambda. It is more sensitive than routine electrophoresis for small monoclonal bands. That is why a report can describe no measurable M-spike yet still identify a small monoclonal protein. [2], [3]
The tests are complementary: SPEP helps measure a quantifiable M-protein, while immunofixation helps characterize it. A positive identification does not show, by itself, how many abnormal plasma cells are in the marrow or whether treatment is necessary.
Antibodies contain heavy chains and light chains. Small amounts of unbound light chains normally circulate in blood. The Kappa/Lambda Light Chains Free with Ratio Blood Test reports the free kappa concentration, free lambda concentration, and kappa-to-lambda ratio. [4]
Read all three results together. Disproportionately increased kappa can raise the ratio; disproportionately increased lambda can lower it. A ratio can also change because the other light chain is suppressed. The direction of the imbalance matters, but an abnormal ratio alone does not identify the underlying disorder.
The kidneys clear free light chains. Reduced filtration can increase both types and may shift the ratio. Inflammation can also increase light-chain production. A mildly abnormal result therefore requires a different interpretation from a marked, persistent imbalance accompanied by a monoclonal band or unexplained organ changes. [4], [5]
The iStopMM study demonstrated why kidney function matters when selecting reference intervals. Later research also proposed age-specific intervals for people with preserved kidney function. These findings support careful laboratory interpretation; they do not mean a patient should substitute an internet range for the interval validated for the performing laboratory’s method. [5], [6]
Review the result alongside creatinine and estimated glomerular filtration rate (eGFR), and compare with prior measurements. Ulta’s Kidney Function Tests guide explains what filtration estimates can and cannot reveal.
Specialists sometimes use an involved-to-uninvolved light-chain ratio. “Involved” means the light chain produced by the abnormal clone. For a kappa-producing clone, this is kappa divided by lambda. For a lambda-producing clone, it is lambda divided by kappa, the reverse of the usual laboratory ratio. [8]
Fictional arithmetic example: free kappa of 10 mg/L and free lambda of 1,000 mg/L give a reported kappa/lambda ratio of 0.01. If lambda is the involved chain, the involved-to-uninvolved ratio is 100. This illustrates the direction of the calculation; it does not diagnose the fictional patient.
A myeloma-defining light-chain result is assessed using the relevant ratio, the absolute involved-chain concentration, and the broader diagnostic criteria. When a light-chain result is the main concerning finding, specialist confirmation and urine assessment are especially important. A numerical flag should never become a self-diagnosis. [8], [13]
Protein studies describe the abnormal protein. Other tests help identify its possible consequences. The CBC assesses hemoglobin, red cells, white cells, and platelets. The CMP includes chemistry measurements relevant to kidney function, calcium, albumin, and total protein. [7]
| Finding | Why it matters | What still needs explanation |
|---|---|---|
| Anemia | May reflect impaired blood production or kidney-related effects. | Blood loss, nutritional deficiencies, inflammation, and other conditions also cause anemia. |
| Reduced kidney function | May signal kidney injury associated with monoclonal proteins. | Dehydration, medicines, diabetes, and other kidney diseases may contribute. |
| High calcium | Can accompany myeloma-related bone disease. | A high value has other causes and must be interpreted with the clinical picture. |
| High total protein or altered albumin/globulin balance | May prompt a closer look at protein patterns. | Total protein does not identify a monoclonal protein; a normal value does not exclude one. |
The abbreviation CRAB refers to elevated calcium, renal impairment, anemia, and destructive bone lesions. To count as myeloma-defining organ damage, the findings must meet the applicable criteria and be attributable to the plasma-cell disorder. Someone can have MGUS and an unrelated cause of anemia or kidney disease. [8], [9]
For a broader discussion of low hemoglobin and alternative causes, see CBC and Anemia Blood Tests. Bone lesions require appropriate imaging; a blood calcium result does not show where a lesion is located. [7], [8]
Additional testing should answer a specific question rather than simply increase the number of results.
The same protein tests may be used across these conditions. Classification depends on the complete evaluation.
| Condition | Main distinction | Usual next step |
|---|---|---|
| MGUS | A monoclonal protein or light-chain abnormality without the defining features of myeloma or an attributable organ-damaging disorder. | Risk assessment and an individualized follow-up plan. |
| Smoldering multiple myeloma | A greater burden of clonal plasma cells and/or monoclonal protein than MGUS, without a myeloma-defining event or amyloidosis. | Specialist risk assessment, monitoring, and discussion of treatment when appropriate. |
| Active multiple myeloma | A qualifying plasma-cell disorder with attributable organ damage or another myeloma-defining event. | Hematology/oncology evaluation and treatment planning. |
This comparison is an educational framework, not a diagnostic or treatment algorithm. Active myeloma can sometimes be diagnosed before symptoms or CRAB damage develop because qualifying marrow, light-chain, or MRI findings establish a myeloma-defining event. [8], [9]
Smoldering myeloma does not always mean observation alone. In November 2025, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma. Eligibility and the balance of treatment benefits and risks require specialist assessment. [11]
Yes. Monoclonal gammopathy of renal significance (MGRS) describes kidney injury from a monoclonal protein in a person whose underlying clone does not meet the usual criteria for an overt blood cancer requiring treatment. The protein’s properties can matter more than its amount.
Unexplained kidney deterioration or protein loss should not be dismissed because the M-spike is small. Equally, kidney disease and a monoclonal protein can coexist for unrelated reasons. Hematology and nephrology assessment, often including a kidney biopsy when appropriate, helps establish the connection. AL amyloidosis is another important consideration when monoclonal light chains and otherwise unexplained organ findings occur together. [12]
No. A clinician may defer marrow biopsy in selected people with low-risk MGUS, reassuring blood counts and chemistry findings, and no concerning symptoms. This decision requires a documented risk assessment and follow-up plan; an M-protein alone does not automatically require biopsy. [10]
When active myeloma is suspected, marrow examination can identify and measure clonal plasma cells. Imaging assesses bone destruction, marrow abnormalities, or masses that laboratory testing cannot show. The specialist may use whole-body low-dose CT, MRI, or PET/CT according to the question. A routine bone-density scan does not substitute for this evaluation. [8]
The examples below are fictional qualitative patterns. They illustrate questions for follow-up and do not diagnose a patient.
| Pattern | Question it raises | Reasonable discussion |
|---|---|---|
| Small monoclonal band; stable blood counts and kidney function; no concerning symptoms | Could this fit a lower-risk monoclonal gammopathy? | Discuss protein type, risk factors, and whether surveillance is appropriate. |
| No measurable M-spike; marked light-chain imbalance; worsening kidney function | Could a light-chain disorder be present despite the electrophoresis result? | Promptly discuss specialist evaluation and appropriate urine studies. |
| Both free light chains elevated; reduced filtration; little imbalance | Could impaired clearance explain the pattern? | Review the assay-specific interval, kidney findings, and other protein results. |
| Established monoclonal protein; new anemia or persistent focal bone pain | Has the condition changed, or is another explanation present? | Review the change promptly; additional testing or imaging may be needed. |
These patterns summarize the relationships discussed above. The same isolated laboratory flag can lead to different next steps depending on the rest of the record.
Confirm the exact order and specimen instructions before collection. The serum free light chain test itself generally requires no special preparation, but other tests collected at the same visit may have different instructions. [4]
Some therapeutic antibodies can appear in protein studies and complicate interpretation. The laboratory may need a specialized method to distinguish treatment-related findings from the patient’s monoclonal protein. Do not stop prescribed treatment to prepare for testing without instructions from the treating team. [14]
The care team chooses measurements that reflect the individual’s disease. A measurable M-protein may be followed with SPEP; light-chain-predominant disease may require particular attention to serum free light chains. Blood counts and chemistry testing help track treatment effects and organ function. [7], [13]
For every comparison, check the test, units, method, collection date, and treatment timing. Use the same laboratory and method when feasible, and flag any change to the care team. A changing ratio may reflect changes in the involved chain, the uninvolved chain, or kidney function; the ratio alone can conceal that distinction. [13]
A lower result does not by itself prove remission, and a single increase does not establish relapse. Formal response assessment may also require urine, marrow, imaging, or specialist residual-disease testing. Use How to Read and Understand Your Lab Results for help distinguishing reference intervals, high or low flags, and clinically meaningful trends.
Arrange a review that brings the protein findings and the clinical picture together. Useful questions include:
Repeating the same test can help confirm a trend, but it cannot answer every diagnostic question. Persistent symptoms or worsening organ function deserve assessment even when a protein result appears reassuring.
Seek emergency evaluation for sudden severe back pain with new leg weakness or numbness, loss of bladder or bowel control, stroke-like symptoms, or severe confusion. These may signal problems that need immediate treatment. Severe breathing difficulty, fainting, or uncontrolled bleeding also require urgent care.
Rapidly worsening weakness, substantially reduced urine output, or symptoms of severe dehydration warrant prompt medical assessment. During cancer treatment, follow the oncology team’s instructions for fever or infection symptoms. Do not wait for routine laboratory testing to address an acute problem. [15]
No. A CBC evaluates blood cells, not the full range of plasma-cell abnormalities. Protein studies and additional assessment may still be appropriate when other findings raise concern.
Yes. Inflammation can increase antibody production and free light-chain levels. The pattern, persistence, clinical history, and accompanying findings help distinguish immune activation from a monoclonal process.
No. An antibody-class concentration measures the total amount of that class. An M-spike represents a restricted protein component. The results answer different questions and should not be treated as interchangeable.
No. Many people with MGUS never develop myeloma. Follow-up depends on their risk profile and health changes; the diagnosis should come with an individualized monitoring plan. [9]
Population screening for MGUS or myeloma is not established routine care. Research into screening does not make an individual test result a diagnosis. Discuss persistent symptoms, relevant history, or unexplained laboratory abnormalities with a healthcare professional. [9]
The test-name links in this guide lead to Ulta Lab Tests listings for the relevant blood and urine studies. Confirm the exact test and collection requirements with the ordering clinician before purchasing, especially when monitoring an established plasma-cell disorder.
Review Direct-Access Lab Testing: How It Works and What to Expect for the ordering and collection process. Bring the complete laboratory report to the clinician responsible for follow-up. Multiple myeloma blood tests are most useful when the abnormal protein, blood counts, kidney function, calcium, symptoms, and specialist findings are interpreted as one clinical picture.
Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
| Category | Linked test name | Role in the article |
|---|---|---|
| Monoclonal-protein detection | Serum Protein Electrophoresis — SPEP | Detecting protein patterns and following measurable M-protein |
| Monoclonal-protein characterization | Serum Immunofixation | Identifying the monoclonal protein type |
| Free-light-chain assessment | Kappa/Lambda Light Chains Free with Ratio Blood Test | Assessing free light-chain concentrations and their ratio |
| Blood counts | Complete Blood Count with Differential and Platelets | Assessing anemia and other blood-cell findings |
| Chemistry and organ-function context | Comprehensive Metabolic Panel | Interpreting kidney, calcium, albumin, and total-protein findings |
| Additional antibody assessment | Total Immunoglobulins Panel for IgA IgG IgM | Measuring major antibody classes |
| Urine protein characterization | Immunofixation Urine Test | Identifying monoclonal proteins in urine |
| Urine protein assessment | Protein Electrophoresis Random Urine Test | Evaluating protein patterns in a random specimen |
| Specialist prognostic assessment | Beta 2 Microglobulin Serum Test | Contributing to specialist risk assessment |
| Specialist prognostic assessment | Lactate Dehydrogenase Test | Providing additional prognostic context |
| Rank | Related Health Area | Relevance |
|---|
| 1 | Multiple Myeloma | Closest condition-specific testing destination |
| 2 | Cancer Screening | Existing parent testing hub |
| 3 | Blood Disorder Tests | Blood-count and plasma-cell testing context |
| 4 | Kidney Tests | Kidney-function and urine-protein context |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
